Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.
Quick Facts
What This Study Found
Both semaglutide and tirzepatide nearly doubled GI side effects versus placebo. Tirzepatide had higher GI risk (RR 2.94) than semaglutide (RR 1.68). Semaglutide increased gallstone risk 2.6-fold but tirzepatide did not.
Key Numbers
13 RCTs; n=26,894; overall GI RR 1.86 (95% CI 1.56-2.21); tirzepatide GI RR 2.94 (95% CI 2.61-3.32); semaglutide GI RR 1.68 (95% CI 1.46-1.94); semaglutide cholelithiasis RR 2.6 (95% CI 1.40-4.82)
How They Did This
Systematic review and meta-analysis of RCTs comparing semaglutide or tirzepatide to placebo in obese adults without diabetes. Pooled risk ratios for GI, biliary, hepatic, and pancreatic adverse events.
Why This Research Matters
With millions using these drugs for weight loss, understanding the distinct GI safety profiles helps clinicians choose the right drug and monitor for specific complications.
What This Study Doesn't Tell Us
Trials had different follow-up durations and doses. Cannot compare semaglutide and tirzepatide directly since they were compared to placebo separately. Limited data on rare events like pancreatic cancer.
Trust & Context
- Original Title:
- Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.
- Published In:
- Annals of Saudi medicine, 45(2), 129-143 (2025)
- Authors:
- Safwan, Moaz, Bourgleh, Mariam Safwan, Alotaibi, Shahad Abdullah, Alotaibi, Eman, Al-Ruqi, Abdulsalam, El Raeya, Fathiya
- Database ID:
- RPEP-13360
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13360APA
Safwan, Moaz; Bourgleh, Mariam Safwan; Alotaibi, Shahad Abdullah; Alotaibi, Eman; Al-Ruqi, Abdulsalam; El Raeya, Fathiya. (2025). Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.. Annals of Saudi medicine, 45(2), 129-143. https://doi.org/10.5144/0256-4947.2025.129
MLA
Safwan, Moaz, et al. "Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.." Annals of Saudi medicine, 2025. https://doi.org/10.5144/0256-4947.2025.129
RethinkPeptides
RethinkPeptides Research Database. "Gastrointestinal safety of semaglutide and tirzepatide vs. p..." RPEP-13360. Retrieved from https://rethinkpeptides.com/research/safwan-2025-gastrointestinal-safety-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.